Lars Zender

USPTO Granted Patents = 4 (Patent Applications = 2)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 6)

Average Co-Inventor Count = 2.2

ph-index = 1

Forward Citations = 25(Granted Patents)

Company Filing History:

3 out of 82

Medizinische Hochschule Hannover

patents

2 out of 23

Helmholtz-Zentrum Fuer Infektionsforschung Gmbh

patents

1 out of 23

Helmholtz-Zentrum Fur Infektionsforschung Gmbh

patents

where one patent can have more than one assignee

Years Active: 2015-2024

Loading Chart...

4 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11975032 - Medicament for liver regeneration and for treatment of liver failure (2024-05-07),

2. 10441577 - Medicament for treatment of liver cancer (2019-10-15),

3. 10188682 - Medicament for liver regeneration and for treatment of liver failure (2019-01-29),

4. 9186381 - Medicament for liver regeneration and for treatment of liver failure (2015-11-17),

Title: Inventor Lars Zender

Introduction: Lars Zender is a renowned inventor based in Braunschweig, Germany, known for his groundbreaking contributions to various technological fields.

Latest Patents: Lars Zender holds several patents in the areas of renewable energy, sustainable transportation, and advanced materials, showcasing his innovative mindset and forward-thinking approach.

Career Highlights: With a career spanning over two decades, Lars Zender has worked with leading research institutions and companies to develop cutting-edge solutions that have had a significant impact on the industry.

Collaborations: Throughout his career, Lars Zender has collaborated with top engineers, scientists, and inventors from around the world, fostering a culture of creativity and excellence in all his projects.

Conclusion: Lars Zender's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and shape the future of technology.

This text is generated by artificial intelligence and may not be accurate.